B
Bull
Bull · 25%PRPH
$0.33
Precio del escenario
$0.363
-0.069 (-18.97%)Al cierre
Loading chart…
- High
- 0.473
- Open
- 0.464
- VWAP
- 0.38
- Vol
- 5.49M
- Mkt Cap
- 81.47M
- Low
- 0.300
- Amount
- 2.08M
- EV/EBITDA, TTM
- 0.00
ProPhase Labs, Inc. is a biotech, genomics, and consumer products company. The Company is engaged in providing whole genome sequencing solutions, diagnostic development, such as its potentially life-saving test for the early detection of esophageal cancer and a direct-to-consumer marketing platform for OTC dietary supplements. It develops, manufactures, and commercializes health and wellness solutions. Its Diagnostic services segment provides diagnostic information services to a range of customers in the United States, including health plans, third-party payers and government organizations. Its Consumer products segment is engaged in the research, development, manufacture, distribution, marketing and sale of OTC consumer healthcare products and dietary supplements in the United States and provides personal genomics products and services. The Company also develops and markets dietary supplements under the TK Supplement brand, which includes Legendz XL and Triple Edge XL.
Métricas de valoración
The current forward P/E ratio for Prophase Labs Inc (PRPH) is 0.00, compared to its 5-year average forward P/E of 4.37.
Alphio AI Price Scenarios for PRPH
Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.
Cronología de eventos
Noticias
9.504-15seekingalphaProPhase Labs Reports FY Loss and Revenue Decline
- 7.502-03seekingalpha
ProPhase Labs Initiates Sale or Partnership Process for BE-Smart Test
7.502-03Yahoo FinanceProPhase Labs Initiates Sale and Partnership Process for BE-Smart™
2.001-05GlobenewswireProPhase Labs Converts $3.3M of Debt, Strengthens Balance Sheet
3.512-19NewsfilterKraig Biocraft Laboratories Transitions to Spider Silk Commercialization with 22% Yield Increase
PRPH FAQ — answered by Alphio AI
ProPhase Labs, Inc. is a biotech, genomics, and consumer products company. The Company is engaged in providing whole genome sequencing solutions, diagnostic development, such as its potentially life-saving test for the early detection of esophageal cancer and a direct-to-consumer marketing platform for OTC dietary supplements. It develops, manufactures, and commercializes health and wellness solutions. Its Diagnostic services segment provides diagnostic information services to a range of customers in the United States, including health plans, third-party payers and government organizations. Its Consumer products segment is engaged in the research, development, manufacture, distribution, marketing and sale of OTC consumer healthcare products and dietary supplements in the United States and provides personal genomics products and services. The Company also develops and markets dietary supplements under the TK Supplement brand, which includes Legendz XL and Triple Edge XL. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).
Esta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.